Top Message
"Driving Sustainable Value Through Growth Investment and Capital Efficiency"
President, Representative Director
I am committed to fulfilling my duties as the new President and Representative Director. I will continue working hard to enhance corporate value by contributing to the improvement of people’s health and progress in society as we diligently safeguard our invaluable foundation and continue to uphold the philosophy that extends back to our founding.
The environment surrounding the pharmaceutical industry is entering an unprecedented era of transformation. To respond to these environmental changes, in 2021, we established ASKA Pharmaceutical Holdings and launched Medium-Term Management Plan 2025.
The fiscal year ended March 31, 2025 (FY2024) marked the fourth year of Medium-Term Management Plan 2025. Driven in part by new products, our business performance built on the previous year’s strengths, with net sales reaching a record high of ¥64.1 billion. Due to higher R&D costs, associated with more active drug discovery research and progress in clinical trials, operating profit declined 18.0% year on year to ¥5.3 billion. Since adopting a holdings structure, revenue has grown for four consecutive years, or six consecutive years if we include results under the previous structure.
As for strengthening shareholder returns, we have continued to maintain stable dividends and now target a consolidated dividend payout ratio of 30% since we adopted a performance-linked profit distribution system for dividends in FY2024. Our dividend forecast for FY2025 includes annual dividends per share of ¥55 and a consolidated payout ratio of 30%.
Going forward, we will continue our proactive efforts to further enhance shareholder returns. We appreciate the continued understanding and support of our shareholders.
Sohta Yamaguchi
President, Representative Director
(As of June 24, 2025)